Actively Recruiting
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Led by University of Wisconsin, Madison · Updated on 2025-10-08
90
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
CONDITIONS
Official Title
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Underwent kidney or simultaneous kidney/pancreas transplant
- Have high-risk CMV serostatus (D+/R-) at the time of transplant
- Developed CMV viremia requiring treatment per institutional protocol
- Show proven or presumed lack of cell-mediated immunity by testing or risk screening
- Able to provide informed consent to participate
You will not qualify if you...
- Allergy or contraindication to letermovir or its components
- Developed ganciclovir-resistant CMV infection
- Currently enrolled in a study involving CMV vaccine or investigational CMV agents
- Unable or unwilling to follow the study protocol as judged by the Investigator
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UW Hospital and Clinics
Madison, Wisconsin, United States, 53792
Actively Recruiting
Research Team
S
Sandesh Parajuli, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here